{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:23:22Z","timestamp":1787844202383,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>Autoantibodies have a role in the diagnosis and prognosis in Autoimmune Inflammatory Myositis (AIM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>The aim of this work was to study the prevalence and clinical correlation of myositis specific and associated antibodies (MSA and MAA) in AIM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting and Design:<\/jats:title>\n                    <jats:p>This was a cross-sectional observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Materials:<\/jats:title>\n                    <jats:p>Consecutive AIM patents were divided into groups as dermatomyositis (DM), polymyositis (PM), CTD-associated myositis (CTD-M), cancer-associated myositis (CAM) and juvenile myositis (JM). Their data along with serum samples were collected after obtaining informed consent. Sera was analyzed for IgG antibodies against Jo-1, PL-7, PL-12, EJ, SRP, Mi-2, MDA-5, TIF1\u03b3, SAE1, SAE2, NXP2 and SSA\/R052kD using the microELISA technique. The institutional ethics committee approved the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Statistical Analysis:<\/jats:title>\n                    <jats:p>\n                      SPSS software (version 24.0) was used.\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value &lt; 0.05 was considered statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There were 48 patients (DM = 19, PM = 19, CTD-M = 5, CAM = 2, JM = 3) included. MSA were positive in 37.5% patients. Antibodies against Mi-2 were present in 6 (12.5%), Jo-1 in 5 (10.4%), 2 (4.1%) each had PL-7 and SRP antibodies. One patient (2%) each had MDA-5, NXP2 and TIf1g antibodies. Jo-1 antibody was associated with mechanic's hands and ILD. There was a significant association of rash in the Mi-2 group with none of the patients having ILD. Malignancy screening was negative in NXP2 and TIF1g antibody-positive patients. Ro52 was the most common MAA (33.3%) and was associated with mechanic's hand.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>MSA was present in almost 40% of the cohort. Anti Jo-1 antibody was associated with mechanic's hands and ILD. None of the Mi-2 patients had ILD, which may point to a protective role of this antibody for ILD. The association of newer antibodies in Indian patients needs to be further studied in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aian.aian_1151_20","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T13:36:22Z","timestamp":1621604182000},"page":"552-558","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["The Association of Myositis Specific Antibodies in Patients with Inflammatory Myositis"],"prefix":"10.4103","volume":"24","author":[{"given":"Natasha Vijay","family":"Negalur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri G.","family":"Ekbote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiren N.","family":"Raval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval V.","family":"Tanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasim S.","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar A.","family":"Bindroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durgarao J.","family":"Yadavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiva","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20240828","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R2-17-20240828","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00002281-199711000-00008","article-title":"Classification criteria for the idiopathic inflammatory myopathies","volume":"9","author":"Targoff","year":"1997","journal-title":"Curr Opin Rheumatol"},{"key":"R3-17-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: New and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"R4-17-20240828","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/BOR.0000000000000548","article-title":"New insights in myositis-specific autoantibodies","volume":"30","author":"Ghirardello","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"R5-17-20240828","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/BOR.0000000000000434","article-title":"Clinical spectrum of anti-Jo-1-associated disease","volume":"29","author":"Monti","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"R6-17-20240828","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: An important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"key":"R8-17-20240828","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Pinal-Fernandez","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"R9-17-20240828","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R10-17-20240828","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10067-016-3453-0","article-title":"Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis","volume":"36","author":"Ceribelli","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R11-17-20240828","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/acr.23188","article-title":"Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res (Hoboken"},{"key":"R12-17-20240828","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/rheumatology\/kex516","article-title":"Muscle ischaemia associated with NXP2 autoantibodies: A severe subtype of juvenile dermatomyositis","volume":"57","author":"Aouizerate","year":"2018","journal-title":"Rheumatology (Oxford"},{"key":"R13-17-20240828","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","article-title":"Anti-TIF1-\u03b3 antibody and cancer-associated myositis: A clinicohistopathologic study","volume":"87","author":"Hida","year":"2016","journal-title":"Neurology"},{"key":"R14-17-20240828","doi-asserted-by":"crossref","first-page":"76129","DOI":"10.18632\/oncotarget.19050","article-title":"Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"R15-17-20240828","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00296-016-3494-3","article-title":"Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis","volume":"36","author":"Srivastava","year":"2016","journal-title":"Rheumatol Int"},{"key":"R17-17-20240828","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10067-018-4267-z","article-title":"Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies","volume":"38","author":"Zampeli","year":"2019","journal-title":"Clin Rheumatol"},{"key":"R18-17-20240828","doi-asserted-by":"crossref","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","article-title":"Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis","volume":"68","author":"Souza","year":"2013","journal-title":"Clinics (Sao Paulo"},{"key":"R19-17-20240828","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","article-title":"Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay","volume":"49","author":"Ghirardello","year":"2010","journal-title":"Rheumatology (Oxford"},{"key":"R20-17-20240828","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14397595.2017.1317377","article-title":"Anti-SS-A\/Ro antibody positivity as a risk factor for relapse in patients with polymyositis\/dermatomyositis","volume":"28","author":"Tatebe","year":"2018","journal-title":"Mod Rheumatol"},{"key":"R21-17-20240828","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/art.1780351014","article-title":"Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations","volume":"35","author":"Oddis","year":"1992","journal-title":"Arthritis Rheum"},{"key":"R22-17-20240828","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MD.0b013e31824d9cec","article-title":"Inflammatory myopathies with anti-Ku antibodies: A prognosis dependent on associated lung disease","volume":"91","author":"Rigolet","year":"2012","journal-title":"Medicine (Baltimore"},{"key":"R23-17-20240828","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/ar4207","article-title":"Implications in the difference of anti-Mi-2 and -p155\/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara?","volume":"15","author":"Petri","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"R24-17-20240828","doi-asserted-by":"crossref","first-page":"100013","DOI":"10.1016\/j.jtauto.2019.100013","article-title":"Frequencies and clinical associations of myositis-related antibodies in The Netherlands: A one-year survey of all Dutch patients","volume":"2","author":"Platteel","year":"2019","journal-title":"J Transl Autoimmun"},{"key":"R25-17-20240828","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00002281-200011000-00001","article-title":"Update on myositis-specific and myositis-associated autoantibodies","volume":"12","author":"Targoff","year":"2000","journal-title":"Curr Opin Rheumatol"},{"key":"R26-17-20240828","doi-asserted-by":"crossref","first-page":"e15578","DOI":"10.1097\/MD.0000000000015578","article-title":"Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis\/dermatomyositis?","volume":"98","author":"Temmoku","year":"2019","journal-title":"Medicine (Baltimore"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.AIAN_1151_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:14:42Z","timestamp":1787843682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.AIAN_1151_20"}},"subtitle":["Preliminary Data in Indian Patients"],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_1151_20","relation":{},"ISSN":["0972-2327"],"issn-type":[{"value":"0972-2327","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}